Table 2. Phase IIb and III, head to head comparative trials with first- and second-generation EGFR TKIs in several settings.
| Study name | Details of the study | PFS (months) | OS (months) | ORR (%) | Ref. |
|---|---|---|---|---|---|
| ICOGEN | Icotinib [200] vs. gefitinib [199]; 51% EGFR-mutant; previously treated; phase III | 4.6 (icotinib) vs. 3.4 (gefitinib); ns | 13.3 (icotinib) vs. 13.9 (gefitinib); ns | 27.6 (icotinib) vs. 27.2 (gefitinib); ns | (52) |
| LUX-Lung 8 | Afatinib [398] vs. erlotinib [397]; squamous-cell lung cancer; previously treated; phase III | 2.4 (afatinib) vs. 1.9 (erlotinib); P=0.0103 | 7.9 (afatinib) vs. 6.8 (erlotinib); P=0.0077 | 6.0 (afatinib) vs. 3.0 (erlotinib); ns | (53) |
| CTONG 0901 | Erlotinib [128] vs. gefitinib [128]; EGFR-mutant; 66% in 1st-line; phase III | 13.0 (erlotinib) vs. 10.4 (gefitinib); ns | 22.9 (erlotinib) vs. 20.1 (gefitinib); ns | 56.3 (erlotinib) vs. 52.3 (gefitinib); ns | (54) |
| LUX-Lung 7 | Afatinib [160] vs. gefitinib [159]; EGFR-mutant; 1st-line; phase IIb | 11.0 (afatinib) vs. 10.9 (gefitinib); P=0.017 | 27.9 (afatinib) vs. 24.5 (gefitinib); ns | 72.5 (afatinib) vs. 56.0 (gefitinib); P=0.0018 | (55,56) |
| ARCHER 1050 | Dacomitinib [227] vs. gefitinib [225]; EGFR-mutant; 1st-line; phase III | 14.7 (dacomitinib) vs. 9.2 (gefitinib); P<0.0001 | 34.1 (dacomitinib) vs. 26.8 (gefitinib); P=0.0438 | 75.0 (dacomitinib) vs. 72.0 (gefitinib); ns | (57,58) |
ns, not significant; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival; ORR, objective response rate.